Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Here's what the landscape actually looks like
48,56,57 For SGLT-2 inhibitors, the major completed CVOTs including empagliflozin in the Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients [EMPA-REG OUTCOME], canagliflozin in the Canagliflozin Cardiovascular Assessment Study [CANVAS Program], and dapagliflozin in the Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 [DECLARE-TIMI 58] trial
It also helps reduce your appetite, helping you feel full longer, which cuts down on unnecessary snacking
The STEP 1 study evaluated the effects of Wegovy in people with a BMI of 27 or higher and found that participants using Wegovy lost an average of 12.4% more weight than those in the placebo group
US$ 25.74
US$ 24.61
US$ 23.73
